Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Acromegaly × lanreotide × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Neuroendocrine Tumors 6 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoid Tumor 2 Serotonin Syndrome 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Intestinal Obstruction 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma 1 Adenoma, Islet Cell 1 Acromegaly 1

Interventions

pasireotide 5 Octreotide 3 Cabergoline 2 pegvisomant 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

Data powered by HemOnc (CC BY 4.0) Colophon ⚡